CCDC106 Inhibitors
CCDC106 inhibitors represent a diverse group of compounds that interfere with various signaling pathways and cellular processes, ultimately leading to decreased activity of the CCDC106 protein. The inhibition mechanisms range from direct kinase inhibition that prevents phosphorylation necessary for CCDC106's function, as seen with staurosporine, to more complex and indirect effects on CCDC106 activity, such as those resulting from the disruption of the PI3K/AKT/mTOR pathway by compounds like LY294002 and wortmannin. These inhibitors, through their targeted actions, can decrease AKT phosphorylation and subsequent downstream signaling events, which may be critical for CCDC106 activity.
The specific inhibition of kinases like MEK, p38 MAP kinase, JNK, mTOR, Src family kinases, FGFR tyrosine kinase, and ROCK by compounds such as PD98059, SB203580, SP600125, rapamycin, PP2, PD173074, and Y-27632, respectively, suggests that CCDC106 is potentially regulated through multiple phosphorylation-dependent mechanisms. Additionally, the proteasome inhibitor bortezomib may decrease CCDC106 activity by affecting protein turnover, highlighting the importance of protein degradation pathways in the regulation of CCDC106.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine acts as a kinase inhibitor, potentially affecting CCDC106 by inhibiting kinase-mediated phosphorylation that may be necessary for CCDC106's functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, leading to decreased AKT phosphorylation. This inhibition could impair CCDC106's function if CCDC106 activity is modulated by the PI3K/AKT signaling axis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK. If CCDC106 activity is regulated through the MAPK/ERK pathway, then this MEK inhibition may reduce CCDC106 functional activity by preventing necessary phosphorylation events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase. This inhibition can reduce phosphorylation of p38 substrates, which may include CCDC106, potentially leading to a decrease in CCDC106's activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, by inhibiting MEK1/2, prevents ERK activation, potentially reducing phosphorylation of CCDC106, assuming CCDC106 is a downstream target, thus inhibiting CCDC106 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that disrupts the PI3K/AKT/mTOR pathway, possibly leading to decreased activity of CCDC106 if it is influenced by this signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, leading to decreased phosphorylation of potential JNK substrates, which might include CCDC106, thereby reducing CCDC106 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key component of the PI3K/AKT/mTOR pathway, potentially decreasing CCDC106 activity by reducing phosphorylation of proteins involved in CCDC106 regulation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor, which could reduce CCDC106 activity if CCDC106 is regulated by Src kinase-mediated phosphorylation. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 inhibits FGFR tyrosine kinase and its downstream signaling pathways; this could decrease CCDC106 activity if CCDC106 is regulated by any pathways downstream of FGFR. | ||||||